APOB

There are 207 papers on APOB in aging research: 33 trials and 111 observational studies in people, 17 in animals, 2 in cells, 42 reviews. The newest story, Nov 9, 2026: “Gene variants linked to higher odds of fatty liver disease”.

Gene

207 papers study it39 findings

HGNCNCBI GeneTaxon

16 new papers in 30 daysSee all 207 papers on APOB

At a glance

The findings reach people, from one lab or study. 19 independent labs in 11 countries.

“neither ApoB levels nor cumulative LDL-C exposure predicted plaque progression in this population of LMHR and near-LMHR individuals”
The Impact of Sustained LDL-C Elevation on Plaque Changes: Primary Coronary plaque progression results from the Keto CTA StudymedRxiv2026doi:10.64898/2026.01.15.26343955

2 of its findings point the other way.

Cells, mice and humans: a single group. Worms or flies: nothing yet.
  • 19 independent labs in 11 countries
  • 2 findings against
  • Funders: National Institutes of Health and others
  • 14 of 38 findings with company ties
  • Human trial33
  • Humans111
  • Animals16
  • Model organisms1
  • Cells2
  • In silico1

Interventions

2

Alirocumab

downin humans1

1 study
  1. Alirocumab decreases APOB in patients with acute myocardial infarction receiving statins.

    “PCSK9 mAb therapy resulted in greater reductions in APOB (apolipoprotein B), APOE (apolipoprotein E), APOC2 (apolipoprotein C2), and APOC3 (apolipoprotein C3)”

    Human trialin patients with acute myocardial infarction receiving statinsplasma

    Integrative Proteomic and Lipidomic Analysis of Patients With Acute Myocardial Infarction Treated With PCSK9 Antibodies and Statins

    Circulation. Genomic and precision medicine

More on Alirocumab

Levocarnitine

downin humans1

1 study
  1. Levocarnitine decreases APOB in humans (type 2 diabetes mellitus) (-7.6 mg/dl (95% CI -13.6 to -1.6)).

    “apolipoprotein-B100 [-7.6 mg/dl (CI95% -13.6 to -1.6); p=0.013]”

    Reviewtype 2 diabetes mellitusoral

    Metabolic effects of L-carnitine on type 2 diabetes mellitus: systematic review and meta-analysis

    Experimental and clinical endocrinology & diabetes : official journal, German Society of Endocrinology [and] German Diabetes Association

More on Levocarnitine

Effects

16

Chronic obstructive pulmonary disease

mediatesin humans1

1 study
  1. APOB is linked with chronic obstructive pulmonary disease in humans (association between artificial sweetener intake and COPD risk) (PM: 6.70%; 95% CI: 3.67%, 16.35%).

    “Beyond lipoprotein sub-fractions, apolipoprotein B served as a significant mediator (PM: 6.70%; 95% CI: 3.67%, 16.35%).”

    Humansassociation between artificial sweetener intake and COPD riskn = 164,656

    Artificial sweetener intake and risk of chronic obstructive pulmonary disease: a mediation analysis based on plasma metabolic biomarkers

    Nutrition & metabolism

More on Chronic obstructive pulmonary disease

Oxidative stress and ROS signaling

upin mice1

1 study
  1. APOB activates oxidative stress and ROS signaling in mice (hAPOB overexpression).

    “Proteomic analyses showed differentially expressed proteins associated with oxidative stress and dendritic remodeling.”

    AnimalshAPOB overexpressionfrontal cortex

    Human APOB-expressing mice translate molecular phenotypes across the Alzheimer's disease spectrum

    Brain, behavior, and immunity

More on Oxidative stress and ROS signaling

Microglial and endothelial cell signatures

downin mice1

1 study
  1. APOB decreases microglial and endothelial cell signatures in mice (hAPOB overexpression).

    “Reduced microglial and endothelial cell signatures were observed through cell type deconvolution”

    AnimalshAPOB overexpressionfrontal cortex

    Human APOB-expressing mice translate molecular phenotypes across the Alzheimer's disease spectrum

    Brain, behavior, and immunity

More on Microglial and endothelial cell signatures

Type I interferon signaling

upin mice1

1 study
  1. APOB activates type I interferon signaling in mice (hAPOB overexpression).

    “hAPOB overexpression in mice induced a robust and persistent upregulation of innate immune genes, particularly those associated with type I interferon responses (Irf7, Ifit1, Oas2)”

    AnimalshAPOB overexpressionfrontal cortex

    Human APOB-expressing mice translate molecular phenotypes across the Alzheimer's disease spectrum

    Brain, behavior, and immunity

More on Type I interferon signaling

Triglyceride

no changein humans1

1 study
  1. APOB showed no clear effect on triglyceride in hypercholesterolemic adults treated with rosuvastatin 20 mg for 3 months (P = .751).

    “TG was not affected (P = .751)”

    Human trialin hypercholesterolemic adults treated with rosuvastatin 20 mg for 3 months3 monthsn = 79

    Preliminary Evidence for the Association of APOB rs1042034 With Short-Term Statin-Induced Lipid Lowering: An Exploratory Study in Vietnam

    Journal of cardiovascular pharmacology and therapeutics

More on Triglyceride

apolipoprotein B secretion

downin human cells1

1 study
  1. APOB decreases apolipoprotein B secretion in human cells (truncated apoB9 expressed in IHH cells).

    “the protein did not exit the endoplasmic reticulum/cis-Golgi and, hence, was not secreted into the media”

    Cellstruncated apoB9 expressed in IHH cellsapoB9 truncated variantimmortalized human hepatocyte

    Identification of a novel apoB variant in a family exhibiting hypocholesterolemia: Mechanistic insights

    Journal of clinical lipidology

Coronary artery disease

downin humans1

1 study
  1. APOB is linked with less coronary artery disease in humans (specifically ApoB100 variants) (P < 0.05).

    “were specifically protective against coronary artery disease (P < 0.05).”

    Humansspecifically ApoB100 variants

    Carriage of rare APOB variants predisposes to severe steatotic liver disease and hepatocellular carcinoma

    The Journal of clinical investigation

More on Coronary artery disease

Hepatic fibrosis

upin humans1

1 study
  1. APOB is linked with higher hepatic fibrosis in clinical cohort (P < 0.05).

    “associated with lower circulating lipids, but higher MASLD activity and fibrosis (P < 0.05).”

    Humansin clinical cohort

    Carriage of rare APOB variants predisposes to severe steatotic liver disease and hepatocellular carcinoma

    The Journal of clinical investigation

Low-density lipoprotein cholesterol

downin humans1−35% lower ldl-c and apob levels

1 study
  1. APOB is linked with lower low-density lipoprotein cholesterol in humans (APOB loss-of-function carriers) (~35% lower LDL-C and apoB levels).

    “APOB carriers had ~35% lower LDL-C and apoB levels, along with reduced total triglycerides and Lp(a) (all p < 0.001).”

    HumansAPOB loss-of-function carriers

    Low Cholesterol due to APOB Variants: Exploring the Balance Between Liver and Cardiovascular Risk

    Liver international : official journal of the International Association for the Study of the Liver

More on Low-density lipoprotein cholesterol

Coronary plaque progression

no changein humans1

1 study
  1. APOB showed no clear effect on coronary plaque progression in lean mass hyper-responders.

    “neither ApoB levels nor cumulative LDL-C exposure predicted plaque progression in this population of LMHR and near-LMHR individuals”

    Human trialin lean mass hyper-respondersone yearn = 100

    The Impact of Sustained LDL-C Elevation on Plaque Changes: Primary Coronary plaque progression results from the Keto CTA Study

    medRxivPreprint

All 16

Associations

19

LDL cholesterol

downin humans1upin humans1

2 studies
  1. APOB is associated with LDL cholesterol in humans (Rare functional APOB variants) (48–53% lower LDL-C).

    “APOB variants were associated with 48–53% lower LDL-C”

    HumansRare functional APOB variants

    Genetically mediated differences in LDL cholesterol were not consistently associated with venous thromboembolism: rare variant analyses in over 700,000 participants

    ESC Congress 2026 abstract

  2. APOB is associated with LDL cholesterol in humans (rs693 Xba I polymorphism; TT homozygotes compared with other genotypes).

    “Statistically significant association was found between Xba I polymorphism and serum LDL, total cholesterol, and total lipid levels, with important elevations among T homozygotes compared to the other genotypes.”

    Humansrs693 Xba I polymorphism; TT homozygotes compared with other genotypesn = 644

    The APOB rs693 polymorphism impacts the lipid profile of Brazilian older adults

    Brazilian journal of medical and biological research = Revista brasileira de pesquisas medicas e biologicas

More on LDL cholesterol

Myocardial infarction

upin humans1downin humans1

1 study
  1. APOB is linked with a higher risk of myocardial infarction in humans (rs693_A allele, in a different population) (β = 0.15, P = 2.8 × 10−3).

    “or increasing MI risks (β = 0.15, P = 2.8 × 10−3 )”

    Humansrs693_A allele, in a different population

    Uncoupling associations of risk alleles with endophenotypes and phenotypes: insights from the ApoB locus and heart-related traits

    Aging cell

  2. APOB is linked with a lower risk of myocardial infarction in humans (rs693_A allele, in one population) (β = -0.18, P = 1.1 × 10−5).

    “This allele shows antagonistic effects-protecting against MI risks (β = -0.18, P = 1.1 × 10−5 )”

    Humansrs693_A allele, in one population

    Uncoupling associations of risk alleles with endophenotypes and phenotypes: insights from the ApoB locus and heart-related traits

    Aging cell

More on Myocardial infarction

FIB-4

upin humans1

1 study
  1. APOB is associated with FIB-4 in humans (ApoB48 pLoF carriers without MAFLD versus non-carriers) (FIB-4: 1.09 vs 0.87, p=0.0003).

    “elevated composite fibrosis score (FIB-4: 1.09 vs 0.87, p=0.0003), while apoB100 carriers showed no such differences.”

    HumansApoB48 pLoF carriers without MAFLD versus non-carriersliver

    Gene variants linked to higher odds of fatty liver disease

    AHA Scientific Sessions 2026 abstract

More on FIB-4

Metabolic dysfunction-associated fatty liver disease

upin humans1OR 3.2

1 study
  1. APOB is linked with a higher risk of metabolic dysfunction-associated fatty liver disease in humans (Heterozygous APOB pLoF carriers in HRN; validated across all cohorts) (OR=3.2).

    “and elevated risk for MAFLD (OR=3.2), which validated across all cohorts.”

    HumansHeterozygous APOB pLoF carriers in HRN; validated across all cohortslivern = 449

    Gene variants linked to higher odds of fatty liver disease

    AHA Scientific Sessions 2026 abstract

More on Metabolic dysfunction-associated fatty liver disease

Hyperlipidemia

downin humans1OR 0.21

1 study
  1. APOB is linked with a lower risk of hyperlipidemia in humans (Heterozygous APOB pLoF carriers in HRN) (OR=0.21).

    “Among 449 HRN participants with APOB pLoFs, we found protection against hyperlipidemia (OR=0.21)”

    HumansHeterozygous APOB pLoF carriers in HRNn = 449

    Gene variants linked to higher odds of fatty liver disease

    AHA Scientific Sessions 2026 abstract

More on Hyperlipidemia

Testicular cancer

downin humans1OR 0.197

1 study
  1. APOB is linked with a lower risk of testicular cancer in humans (genetically proxied inhibition, drug-target Mendelian randomization) (OR 0.197 (95% CI 0.089-0.438)).

    “In testicular cancer, inhibition of NPC1L1 (OR =0.017; 95% CI: 0.001-0.295) and APOB (OR =0.197; 95% CI: 0.089-0.438) was associated with reduced risk.”

    Humansgenetically proxied inhibition, drug-target Mendelian randomization

    The role of lipid-lowering drugs in urologic and male reproductive cancers: a Mendelian randomization study

    Translational andrology and urology

More on Testicular cancer

HDL-C

downin humans1

1 study
  1. APOB is associated with HDL-C in hypercholesterolemic adults treated with rosuvastatin 20 mg for 3 months (β = -0.121, P = .004).

    “lower posttreatment HDL-C (β = -0.121; P = .004)”

    Human trialin hypercholesterolemic adults treated with rosuvastatin 20 mg for 3 months3 monthsn = 79

    Preliminary Evidence for the Association of APOB rs1042034 With Short-Term Statin-Induced Lipid Lowering: An Exploratory Study in Vietnam

    Journal of cardiovascular pharmacology and therapeutics

More on HDL-C

LDL-C

upin humans1

1 study
  1. APOB is associated with LDL-C in hypercholesterolemic adults treated with rosuvastatin 20 mg for 3 months (β = 0.758, P = .001).

    “ANCOVA (adjusting for baseline) showed the TT genotype was independently associated with higher posttreatment LDL-C (β = 0.758; P = .001)”

    Human trialin hypercholesterolemic adults treated with rosuvastatin 20 mg for 3 months3 monthsn = 79

    Preliminary Evidence for the Association of APOB rs1042034 With Short-Term Statin-Induced Lipid Lowering: An Exploratory Study in Vietnam

    Journal of cardiovascular pharmacology and therapeutics

More on LDL-C

Hepatocellular carcinoma

upin humans1OR 3.53

1 study
  1. APOB is linked with a higher risk of hepatocellular carcinoma in humans (cross-ancestry meta-analysis) (pooled OR 3.53, 95% CI: 2.09-5.98).

    “yielded pooled ORs for cirrhosis and hepatocellular carcinoma (HCC) of 1.82, 95% CI: 1.33-2.49 and 3.53, 95% CI: 2.09-5.98, respectively.”

    Humanscross-ancestry meta-analysis

    Carriage of rare APOB variants predisposes to severe steatotic liver disease and hepatocellular carcinoma

    The Journal of clinical investigation

More on Hepatocellular carcinoma

Cirrhosis

upin humans1OR 1.82

1 study
  1. APOB is linked with a higher risk of cirrhosis in humans (cross-ancestry meta-analysis) (pooled OR 1.82, 95% CI: 1.33-2.49).

    “Cross-ancestry meta-analysis of the study cohorts yielded pooled ORs for cirrhosis and hepatocellular carcinoma (HCC) of 1.82, 95% CI: 1.33-2.49”

    Humanscross-ancestry meta-analysis

    Carriage of rare APOB variants predisposes to severe steatotic liver disease and hepatocellular carcinoma

    The Journal of clinical investigation

More on Cirrhosis

All 19

Funding

1 grant since 2026

National Heart, Lung, and Blood Institute$310K

Latest

Dec 2025: 5Jan 2026: 22Feb 2026: 19Mar 2026: 12Apr 2026: 4May 2026: 5Jun 2026: 4Jul 2026: 6Aug 2026: 8Sep 2026: 11Oct 2026: 7Nov 2026: 9112 papers in 12 months
AHA Scientific Sessions 2026 Abstract

Gene variants linked to higher odds of fatty liver disease

In 402,437 people, variants disrupting one copy of a fat-transport gene were linked to higher fatty liver odds, with an odds ratio of 3.2 versus non-carriers.In 402,437 people, variants disrupting one copy of a fat-transport gene were linked to higher fatty liver odds, with an odds ratio of 3.2 versus non-carriers.

Genetic association · 402,437 peopleMechanisms

See all 207 papers on APOB